Hamsters as a model of severe acute respiratory syndrome coronavirus-2
AM Braxton, PS Creisher, CA Ruiz-Bedoya… - Comparative …, 2021 - ingentaconnect.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus
disease 2019 (COVID-19), rapidly spread across the world in late 2019, leading to a …
disease 2019 (COVID-19), rapidly spread across the world in late 2019, leading to a …
AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection
AA Aksyuk, H Bansal, D Wilkins, AM Stanley… - Cell Reports …, 2023 - cell.com
The nasal mucosa is an important initial site of host defense against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection. However, intramuscularly administered …
syndrome coronavirus 2 (SARS-CoV-2) infection. However, intramuscularly administered …
A bacteriophage-based, highly efficacious, needle-and adjuvant-free, mucosal COVID-19 vaccine
ABSTRACT The US Food and Drug Administration-authorized mRNA-and adenovirus-
based SARS-CoV-2 vaccines are intramuscularly injected in two doses and effective in …
based SARS-CoV-2 vaccines are intramuscularly injected in two doses and effective in …
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa
B Vesin, J Lopez, A Noirat, P Authié, I Fert… - Molecular Therapy, 2022 - cell.com
As the coronavirus disease 2019 (COVID-19) pandemic continues and new severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern emerge, the adaptive …
respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern emerge, the adaptive …
Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration
Many of the current pandemic threats are caused by viruses that infect the respiratory tract.
Remarkably though, the majority of vaccines and antiviral drugs are administered via …
Remarkably though, the majority of vaccines and antiviral drugs are administered via …
A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice
The continued emergence of SARS-CoV-2 variants and the threat of future Sarbecovirus
zoonoses have spurred the design of vaccines that can induce broad immunity against …
zoonoses have spurred the design of vaccines that can induce broad immunity against …
The highly conserved stem-loop II motif is dispensable for SARS-CoV-2
The stem-loop II motif (s2m) is an RNA structural element that is found in the 3′
untranslated region (UTR) of many RNA viruses, including severe acute respiratory …
untranslated region (UTR) of many RNA viruses, including severe acute respiratory …
mRNA-1273 and Ad26. COV2. S vaccines protect against the B. 1.621 variant of SARS-CoV-2
TL Darling, B Ying, B Whitener, LA VanBlargan… - Med, 2022 - cell.com
Background Since the emergence of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) in 2019, viral variants with greater transmissibility or immune-evasion …
(SARS-CoV-2) in 2019, viral variants with greater transmissibility or immune-evasion …
Prototype and BA. 5 protein nanoparticle vaccines protect against Omicron BA. 5 variant in Syrian hamsters
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
with greater transmissibility or immune evasion properties has jeopardized the existing …
with greater transmissibility or immune evasion properties has jeopardized the existing …
Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals
The COVID-19 pandemic has emphasized the importance and need for accessible safe,
effective, and versatile vaccine platforms. While approved SARS-CoV-2 vaccines have been …
effective, and versatile vaccine platforms. While approved SARS-CoV-2 vaccines have been …